EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Association of circulating Z‐polymer with adverse clinical outcomes and liver fibrosis in adults with alpha‐1 antitrypsin deficiency

Malin Fromme, Laura Rademacher, Samira Amzou, Christi D Cook, Isabel Zacharias, Lanju Zhang, John E Ripollone, Pavel Strnad iD

United European Gastroenterology Journal · 2024

DOI: 10.1002/ueg2.12629 ↗

Kurz gefasst

Fachartikel in der Zeitschrift United European Gastroenterology Journal, 2024. Verfasst von Malin Fromme und 7 weiteren Autor:innen. Beteiligte Einrichtung: Medical Clinic III, Gastroenterology, Metabolic Diseases and Intensive Care, University Hospital RWTH Aachen, Health Care Provider of the European Re…. Hauptthemen laut MEDLINE: alpha 1-Antitrypsin Deficiency, Liver Cirrhosis, alpha 1-Antitrypsin, Genotype. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Vertex Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Circulating polymerized mutant Z‐alpha‐1 antitrypsin (Z‐polymer) constitutes a characteristic feature in alpha‐1 antitrypsin deficiency (AATD), but there is limited knowledge about its association with adverse clinical outcomes and liver fibrosis. We explored this association using data from a large cohort of adults with AATD.

Methods

A total of 836 (431 PiZZ, 405 PiMZ) adults with AATD and 312 controls (PiMM) from the European Alpha‐1 Liver Cohort (2015–2020) were included. Time‐to‐event analyses were conducted for adults with the PiZZ genotype followed for adverse clinical outcomes (earliest occurrence of liver‐related hospitalization, liver transplant or all‐cause mortality). Cox proportional hazard models were used to describe the association between binary circulating Z‐polymer levels and adverse clinical outcomes. Correlations between baseline circulating Z‐polymer levels and baseline liver fibrosis (liver stiffness measurement [LSM] determined by transient elastography [FibroScan®]) were evaluated. The analyses were stratified by augmentation therapy status.

Results

Of 324 adults with the PiZZ genotype and longitudinal follow‐up data, 28 reported adverse clinical outcomes. Higher baseline circulating Z‐polymer levels were associated with an increased risk of adverse clinical outcomes in both crude (hazard ratio [95% confidence interval, CI], 2.88 [1.21, 6.87]) and age‐adjusted (1.96 [0.78, 4.94]) analyses. In adults with the PiZZ genotype, circulating Z‐polymer levels were weakly positively correlated with baseline LSM (Spearman's rho [95% CI]: 0.21 [0.11, 0.31]). Similar results were observed after stratification by augmentation therapy status.

Conclusions

In adults with the PiZZ genotype, higher circulating Z‐polymer levels were associated with a shorter time to adverse clinical outcome, and positively correlated with baseline LSM. Circulating Z‐polymer levels may be a prognostic biomarker of clinically relevant disease in AATD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

alpha 1-Antitrypsin DeficiencyLiver Cirrhosisalpha 1-AntitrypsinGenotypeHumansMaleFemaleMiddle AgedAdultLiver TransplantationElasticity Imaging TechniquesBiomarkersAgedMutationProportional Hazards ModelsCase-Control StudiesLiver

Stichwörter der Autor:innen

FibroScan®SERPINA1alpha‐1 antitrypsin deficiencyaugmentation therapyliver fibrosistransient elastography

Substanzen

alpha 1-AntitrypsinBiomarkersSERPINA1 protein, human

Autor:innen und Institutionen

  • Medical Clinic III, Gastroenterology, Metabolic Diseases and Intensive Care, University Hospital RWTH Aachen, Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN RARE LIVER), Aachen, Germ…
  • Vertex Pharmaceuticals, Boston, Massachusetts, USA.

ORCID-Profile: Pavel Strnad

Förderung

  • Vertex Pharmaceuticals

Zitieren

APA

Fromme, M., Rademacher, L., Amzou, S., Cook, C. D., Zacharias, I., Zhang, L., Ripollone, J. E., & Strnad, P. (2024). Association of circulating Z‐polymer with adverse clinical outcomes and liver fibrosis in adults with alpha‐1 antitrypsin deficiency. United European Gastroenterology Journal. https://doi.org/10.1002/ueg2.12629

Vancouver

Fromme M, Rademacher L, Amzou S, Cook CD, Zacharias I, Zhang L, et al. Association of circulating Z‐polymer with adverse clinical outcomes and liver fibrosis in adults with alpha‐1 antitrypsin deficiency. United European Gastroenterology Journal. 2024. doi:10.1002/ueg2.12629

BibTeX
@article{Fromme2024,
  author = {Fromme, Malin and Rademacher, Laura and Amzou, Samira and Cook, Christi D and Zacharias, Isabel and Zhang, Lanju and Ripollone, John E and Strnad, Pavel},
  title = {Association of circulating Z‐polymer with adverse clinical outcomes and liver fibrosis in adults with alpha‐1 antitrypsin deficiency},
  journal = {United European Gastroenterology Journal},
  year = {2024},
  doi = {10.1002/ueg2.12629}
}
Kostenlos starten →